Key research priorities include refining epidemiological estimates, standardizing biomarker cut-offs, elucidating dynamic interactions between alcohol and CMRFs, validating non-invasive prognostic tools, and evaluating therapies that target both metabolic and alcohol-related injury.
Chronic liver disease is a leading cause of global morbidity and mortality, with an evolving etiologic landscape driven by rising metabolic dysfunction and persistent alcohol use. The introduction of metabolic and alcohol-associated liver disease (MetALD) recognizes the coexistence of these exposures as dual drivers of...
Gurmehr Brar, Brian P. Lee· Hepatology Communications· 0 citations
Background: Alcohol-associated liver disease (ALD) is a leading cause of advanced liver disease and liver transplantation worldwide. Cardiometabolic risk factors (CMRFs) may worsen ALD prognosis. While recent nomenclature acknowledges the impact of CMRFs in steatotic liver disease with low-to-moderate alcohol use, indi...
Dhiraj K Peddu, Vitchapong Prasitsumrit, Matthew Kubina et al.· Hepatology Communications· 0 citations
BACKGROUND AND AIMS
Alcohol consumption is a leading cause of liver-related morbidity and mortality, with dose-dependent effects on liver outcomes. However, a weakening association between alcohol consumption and liver-related mortality has been suggested. As metabolic burden increases and may act synergistically with...
Eneli Katunin, V. Männistö, F. Åberg· Liver international (Print)· 0 citations
Metabolic dysfunction-associated steatotic liver disease with increased alcohol consumption (MetALD) is a newly defined category within the spectrum of steatotic liver disease. It captures patients who have both cardiometabolic risk factors and alcohol intake above the thresholds accepted for metabolic dysfunction-asso...
Reliance on invasive liver biopsy endpoints is a major limiting factor in new therapeutic development for metabolic dysfunction-associated steatohepatitis (MASH). While liver fat accumulation is considered a driver of early disease, liver fat reduction is not recognized as a surrogate endpoint by health authorities. He...
N. Verweij, G. Hindy, Q. Nguyen et al.· medRxiv· 0 citations
Accurate classification and risk stratification across metabolic dysfunction-associated steatotic liver disease (MASLD), MetALD, and alcohol-associated liver disease (ALD) depend critically on the assessment of alcohol exposure. However, current clinical practice relies largely on self-reported alcohol intake, which ma...
Hyo Young Lee, E. Yoon, D. Jun· Clinical and Molecular Hepat...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
